A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

BACKGROUND: Activation of the mammalian target of rapamycin (mTOR) pathway is observed in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in this population. We evaluate the efficacy of the ora...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Neuro Oncol
Główni autorzy: Ullrich, Nicole J, Prabhu, Sanjay P, Reddy, Alyssa T, Fisher, Michael J, Packer, Roger, Goldman, Stewart, Robison, Nathan J, Gutmann, David H, Viskochil, David H, Allen, Jeffrey C, Korf, Bruce, Cantor, Alan, Cutter, Gary, Thomas, Coretta, Perentesis, John P, Mizuno, Tomoyuki, Vinks, Alexander A, Manley, Peter E, Chi, Susan N, Kieran, Mark W
Format: Artigo
Język:Inglês
Wydane: Oxford University Press 2020
Hasła przedmiotowe:
Pediatric Neuro-Oncology
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7566451/
https://ncbi.nlm.nih.gov/pubmed/32236425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa071
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy